Cyproterone acetate (CPA) is a progestogen and antiandrogen steroid medication that is used primarily in the treatment of prostate cancer, precocious puberty, acne, and excessive hair growth in women. It acts as a progesterone agonist or antagonist and as an antiandrogen by competing for the androgen receptor. CPA was one of the earliest clinically used antiandrogens and remains an important medication in clinical use today. It is available both as a standalone medication and in combination with an estrogen under various brand names throughout the world.
Market Dynamics:
The global cyproterone acetate market is driven by the increasing incidence of prostate cancer in men, and rising cases of acne and hirsutism in women. Moreover, shifting lifestyle patterns and growing geriatric population are major factors fueling the market growth. However, side effects associated with the long-term use of cyproterone acetate such as liver toxicity, fatigue, and depression along with the availability of alternative medications are expected to hamper market expansion to some extent. The development of conjugated forms of CPA with improved safety profiles can create lucrative opportunities over the forecast period.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook